Novo Nordisk shares climb after positive results for anti-obesity pill
1. Novo Nordisk's market value rose by £9bn after new weight-loss pill data. 2. Shares increased over 6%, aiming to regain market share against Eli Lilly. 3. Novo's tablet Wegovy may replicate injection results with significant weight loss. 4. FDA approval expected soon, production has begun at US sites. 5. Analysts forecast peak sales of $5bn for Novo's oral obesity drug.